Neurim Pharmaceuticals Ltd
Ran Furman is an experienced biochemist and scientific leader with a robust background in drug discovery and development. Currently serving as the Head of Discovery and Preclinical at Neurim Pharmaceuticals Ltd since September 2022, Ran leads target identification efforts for new drug candidates and manages the company's R&D program, overseeing patents and communication with academic labs and Contract Research Organizations. Previous roles include Senior Scientist at Bristol-Myers Squibb, where Ran acted as the Scientific Leader for various therapeutic areas, and positions at the University of Pennsylvania, Siemens Healthineers, The Ohio State University, and Tel Aviv University, emphasizing expertise in mass spectrometry, protein characterization, and molecular biology techniques. Educational qualifications include a Ph.D. in Microbiology from The Ohio State University and a Master’s and Bachelor’s degree in Microbiology and Life Sciences from Tel Aviv University.
This person is not in the org chart
Neurim Pharmaceuticals Ltd
Neurim Pharmaceuticals is a neuroscience drug discovery and development company creating drugs for brain restoration & reinforcement, focusing on the central nervous system. With a proven track record of drug development and commercialization, Neurim’s first products, Circadin® and Slenyto® , are already in use in more than 40 countries across 5 continents. Constantly expanding into additional therapeutic areas, the R&D pipeline comprises new products that address insomnia, Alzheimer’s dementia and sleep apnea.